MCL1 and hematologic disorder: These compounds are characterized by their impressive potency, on-target activity (i.e., BAK dependent induction of apoptosis), a stabilizing effect on MCL-1 protein at least in non-sensitive cells, an inverse correlation between activity and BCL-xL expression levels as well as their preferential activity in hematological malignancies.